Vico Therapeutics, a Leiden, The Netherlands-based clinical-stage genetic medicines company, raised EUR11.5M in the second closing of its Series B funding.
Backers included Seroba, and Kurma Partners, via the Kurma Growth Opportunities Fund. They joined Ackermans & van Haaren (AvH), Droia Ventures, EQT Life Sciences, Eurazeo, Kurma Biofund, Polaris Partners and Pureos Bioventures, for a total Series B financing round of €65.8M ($70.7M).
The company intends to use the funds to continue to advance their lead clinical program and further develop a portfolio of novel antisense oligonucleotides.
Vico Therapeutics is a clinical-stage genetic medicines company developing therapies for severe neurological diseases. Its lead program VO659 is currently in a Phase 1/2a clinical study of patients with spinocerebellar ataxia types 3 and 1 and Huntington’s disease, devastating neurodegenerative diseases for which there are currently no disease-modifying treatments available.
FinSMEs
24/06/2024